Ashwagandha for Chemotherapy-Related Fatigue in Breast Cancer
Ashwagandha for Chemotherapy-Related Fatigue in Breast Cancer
Biswal and colleagues conducted a randomized clinical study evaluating whether Withania somnifera (ashwagandha) could reduce chemotherapy-induced fatigue and improve quality of life in women receiving treatment for breast cancer. Fatigue is one of the most common and distressing side effects of chemotherapy, often persisting long after treatment ends. This study aimed to explore whether an adaptogenic botanical could offer meaningful support during active care.
The trial enrolled women undergoing standard chemotherapy and randomized them to receive either ashwagandha or placebo throughout their treatment cycles. Participants in the intervention group took 2 grams of ashwagandha per day, divided into two doses. The comparison group received a matching placebo. Outcomes were measured using validated fatigue scales, quality-of-life assessments, and symptom questionnaires administered at multiple points during treatment.
Results showed that patients receiving ashwagandha experienced significantly lower levels of fatigue compared to placebo. Improvements were observed both in physical tiredness and in emotional resilience, with participants reporting better sleep quality, energy, and daily functioning. Quality-of-life scores also improved in the ashwagandha group, suggesting benefits beyond fatigue reduction. Importantly, the supplement was well tolerated, with no increase in concerning side effects.
For patients undergoing chemotherapy who struggle with persistent exhaustion, this study offers encouraging evidence that ashwagandha may provide supportive relief. As always, integration with conventional care and practitioner guidance is essential, but these findings highlight a promising option for enhancing well-being during a demanding phase of treatment.
Reference:
Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2012;12(4):312-322. doi:10.1177/1534735412464551.
